MDAnderson Cancer Center
Welcome,         Profile    Billing    Logout  
 23 Trials 
18 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Slingluff, Craig L
Mel-65, NCT03617328: Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Completed
1/2
33
US
6MHP, 6 melanoma helper peptide vaccine, Montanide ISA-51, polyICLC, CDX-1127, Varlilumab
Craig L Slingluff, Jr, Celldex Therapeutics
Melanoma
01/24
01/24
Mel66, NCT04364230: Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Active, not recruiting
1/2
22
US
6MHP, 6 melanoma helper peptide vaccine, NeoAg-mBRAF, BRAF 585-614 (V600E), PolyICLC, CDX-1140
Craig L Slingluff, Jr, Celldex Therapeutics
Melanoma, Ocular Melanoma, Uveal Melanoma
09/24
05/25
AM-003, NCT04116320: Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Active, not recruiting
1
5
US
Echopulse, Focused Ultrasound Ablation, FUSA, Poly ICLC, Hiltonol, Standard of Care PD-1 Therapy
Craig L Slingluff, Jr, Theraclion
Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
02/24
02/24
Cortes, Jorge
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
NCT00930540: DB-67 in Myelodysplastic Syndrome (MDS)

Active, not recruiting
2
25
US
AR-67 (DB-67), DB-67, 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin
M.D. Anderson Cancer Center, Arno Therapeutics
Myelodysplastic Syndrome
12/15
 
ASC4MORE, NCT03578367 / 2018-001594-24: Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Active, not recruiting
2
104
Europe, Canada, US, RoW
Asciminib add-on, ABL001 (asciminib), Imatinib, STI571, Nilotinib, AMN107, Asciminib single agent
Novartis Pharmaceuticals
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
11/21
02/25
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Recruiting
2
182
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
02/26
02/27
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
NCT03038230: MCLA-117 in Acute Myelogenous Leukemia

Checkmark Data from trial for AML at EHA 2020
Jun 2020 - Jun 2020: Data from trial for AML at EHA 2020
Checkmark Initial data in AML
May 2020 - May 2020: Initial data in AML
Checkmark Planned clinical update
More
Active, not recruiting
1
62
Europe, US
MCLA-117 bispecific antibody, bispecific, human bispecific common light chain, bispecific IgG1 targeting CLEC12A and CD3
Merus N.V.
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
07/21
07/21
Cinciripini, Paul
NCT02162849: Reward Sensitivity and Pharmacotherapy for Smoking Cessation

Active, not recruiting
4
204
US
Varenicline, Chantix, Nicotine Patch, Placebo Patch, Placebo Tablet, Sugar pill, Questionnaires, Surveys, Counseling Sessions, Lab Session, Saliva Test
M.D. Anderson Cancer Center, NAL PHARMA, Pfizer
Tobacco Use Cessation
06/25
06/25
NCT03059940: Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer

Active, not recruiting
1
630
US
Questionnaires, Surveys, Low Dose Computed Tomography Scan, LDCT, Shared Decision Making + Video, Cessation Counseling, Quitline, Pharmacotherapy Discussion, Nicotine Patch, Anti-Smoking Drug, Tobacco Treatment Program, TTP, Carbon Monoxide (CO) Level Test, CO
M.D. Anderson Cancer Center, National Cancer Institute (NCI), Pfizer
Smoking Cessation
06/24
06/24
Patel, Sapna P
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
380
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics U.S., Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
09/23
12/26
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
380
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab, Keytruda, pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
Syntrix-SX682-Melanoma-101, NCT03161431: SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Checkmark Anticipated initial clinical data in combination with SX-682 for metastatic melanoma
Oct 2020 - Oct 2020: Anticipated initial clinical data in combination with SX-682 for metastatic melanoma
Recruiting
1
77
US
SX-682, Pembrolizumab, KEYTRUDA
Syntrix Biosystems, Inc., Massachusetts General Hospital, National Cancer Institute (NCI), Dana-Farber Cancer Institute, Mayo Clinic, University of Rochester, M.D. Anderson Cancer Center, University of Miami
Melanoma Stage III, Melanoma Stage IV
06/25
06/26
NCT04879017: FHD-286 in Subjects With Metastatic Uveal Melanoma

Terminated
1
76
Europe, US
FHD-286
Foghorn Therapeutics Inc.
Metastatic Uveal Melanoma
11/23
11/23
NCT04109456: IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Recruiting
1
120
US, RoW
IN10018, BI 853520, Cobimetinib, Cotellic, Atezolizumab
InxMed (Shanghai) Co., Ltd.
Metastatic Melanoma
06/24
09/24
TS-PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
Balmes, Gener
No trials found

Download Options